EUCTR2006-000821-74-DE进行中（未招募）不适用
A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem cell transplantation - Traumeel
niversity Hospital of Muenster0 个研究点目标入组 0 人开始时间: 2006年10月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients = 2 years, undergoing allogeneic stem cell transplantation, receiving any type of myeloablative high-dosis-chemotherapie with/without TBI = 8 Gy
- •-Adults: written inform consent of full age subjects
- •-Children: written inform consent of the parents/guardian and as possible of the children themselves after information
- •-Availability of negative pregnancy test and adequate contraceptive measures for female patients of childbearing age
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-No written informed consent
- •-Pregnant or nursing patients
- •-Prior inclusion in this study
- •-Patients with known allergy to an ingredient of Traumeel® S
- •-Patients with other condition or illness, which in estimation of the investigator couldn’t be treated as written in protocol.
研究者
相似试验
进行中（未招募）
1 期
Study of capmatinib and spartalizumab in lung cancerEUCTR2019-003097-11-ITOVARTIS PHARMA AG31
进行中（未招募）
1 期
Study of capmatinib and spartalizumab in lung cancernon-small cell lung cancer with MET exon 14 skipping mutationsMedDRA version: 20.1Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2019-003097-11-DEovartis Pharma AG270
终止
2 期
Study of efficacy and safety of capmatinib in combination with spartalizumab in naive patients with EGFR wild type (wt), ALK rearrangement negative advanced NSCLC, harboring MET exon 14 skipping mutations.on small cell lung cancer(NSCLC)JPRN-jRCT2080225343ovartis Pharma. K.K.270
进行中（未招募）
1 期
Study of capmatinib and spartalizumab in lung cancernon-small cell lung cancer with MET exon 14 skipping mutationsMedDRA version: 20.1Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2019-003097-11-BEovartis Pharma AG270
进行中（未招募）
1 期
Study of capmatinib and spartalizumab in lung cancernon-small cell lung cancer with MET exon 14 skipping mutationsMedDRA version: 20.1Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2019-003097-11-FRovartis Pharma AG270